TD Cowen Reiterates Buy Rating on Royalty Pharma plc (RPRX)

Market Context

Royalty Pharma plc operates in the Healthcare sector. The stock currently trades at $56.45 with a market capitalization of $16.8B. The stock has gained 57.3% over the past 52 weeks.

Analyst coverage from TD Cowen provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Royalty Pharma plc.

Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.

Recent Analyst Activity for Royalty Pharma plc

Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.

Date	Firm	Rating	Price Target
Jul 13, 2026	TD Cowen	Buy	N/A
May 07, 2026	JP Morgan	Overweight	N/A
May 07, 2026	Citigroup	Buy	N/A
Apr 21, 2026	UBS	Buy	N/A
Apr 10, 2026	Morgan Stanley	Overweight	N/A

Related Tools: Analyst Ratings Dashboard | View RPRX Stock Page